The Latest Breaking News from Novo

Eli Lilly said Tuesday it plans to advance its next-generation obesity treatment into final-phase testing, but LLY stock dipped on guidance.

A new generation of FDA-approved diabetes drugs that can also help patients lose weight has prompted enthusiasm from doctors and a firestorm of demand among patients so strong it's led to shortages.

A key decision from Eli Lilly could alight the obesity treatment landscape again, an analyst said Friday as LLY stock lingers near a record.

Amgen is years behind rivals in developing an obesity treatment, but the company says its experimental drug could prove superior.

Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.

Novo Nordisk A/S’s weekly shot that reduces obesity in adults returned promising results in teens, according to a study that adds to a growing wave of potential interventions for the stubborn condition.

Excitement is building about a new generation of drugs that tout the ability to help adults with excess weight shed more pounds than older drugs on the market.

Amgen stock surged Tuesday on a reportedly bullish call for its experimental obesity treatment — a potential rival to Novo and Lilly.

LOS ANGELES — In September, Steve Lacy sauntered into the glassy upstairs lounge at the Novo in downtown L.A. bearing some remarkable news. The 24-year-old, Compton-raised singer-songwriter, dressed in a flowy trench coat, shoulder-length braids and imposing full-face sunglasses, had just learned that "Bad Habit," his bummed-out yet deliriously horny…

Novo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying.

A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.